Detection of citrate overdose in critically ill patients on citrate-anticoagulated venovenous haemofiltration: use of ionised and total/ionised calcium

Andries J. Bakker 1. , 1. , E. Christiaan Boerma 2. , 2. , Halbe Keidel 3. , 3. , Peter Kingma 4. , 4.  and Peter H.J. van der Voort 5. , 5.
  • 1. Department of Clinical Chemistry, Stichting Klinisch Chemisch Laboratorium, Leeuwarden, The Netherlands
  • 2. Department of Intensive Care Medicine, Medical Centre Leeuwarden, Leeuwarden, The Netherlands
  • 3. Department of Clinical Chemistry, Stichting Klinisch Chemisch Laboratorium, Leeuwarden, The Netherlands
  • 4. Department of Intensive Care Medicine, Medical Centre Leeuwarden, Leeuwarden, The Netherlands
  • 5. Department of Intensive Care Medicine, Medical Centre Leeuwarden, Leeuwarden, The Netherlands

Abstract

Background: The objective of this study was to elucidate the most practical and effective laboratory measurement for monitoring citrate in critically ill patients undergoing citrate-anticoagulated continuous venovenous haemofiltration (CVVH).

Methods: This observational study was performed at the mixed medical and surgical intensive care unit of a regional teaching hospital. The study population comprised ten consecutive critically ill patients with acute renal failure and indication for haemofiltration with the use of regional anticoagulation with citrate. Serum samples for the measurement of citrate and total and ionised calcium were taken from the pre- and post-filter compartments and from the arterial circulation of patients during citrate-anticoagulated CVVH.

Results: Receiver operating characteristic (ROC) curve analysis showed that for detecting citrate overdose (defined as a citrate concentration >1.0mmol/L) the best cut-off limits for total/ionised calcium and ionised calcium were 2.1 and 0.8mmol/L, respectively. Sensitivity and specificity for the cut-off limit of 2.1 for total/ionised calcium were 89% and 100%, and 84% and 100%, respectively, for the cut-off limit of 0.8mmol/L for ionised calcium.

Conclusions: In patients without liver insufficiency, total/ionised calcium performed slightly better than ionised calcium in detecting elevated citrate concentrations. However, because of the simplicity of its measurement, ionised calcium is preferred. Measurement of citrate is not necessary.

Clin Chem Lab Med 2006;44:962–6.

  • 1.

    Gibney RT, Stollery DE, Lefebvre RE, Sharun CJ, Chan P. Continuous arteriovenous hemodialysis: an alternative therapy for acute renal failure associated with critical illness. Can Med Assoc J 1988; 139:861–6.

  • 2.

    Ronco C. Continuous renal replacement therapies for the treatment of acute renal failure in intensive care patients. Clin Nephrol 1993; 40:187–98.

  • 3.

    Favre H, Martin PY, Stoermann C. Anticoagulation in continuous extracorporeal renal replacement therapy. Semin Dial 1996; 9:112–8.

  • 4.

    Flanigan MJ, VonBrecht J, Freeman RM, Lim VS. Reducing the hemorrhagic complications of hemodialysis: a controlled comparison of low dose heparin and citrate anticoagulation. Am J Kidney Dis 1987; 9:147–53.

  • 5.

    Palsson R, Niles JL. Regional citrate anticoagulation in continuous venovenous hemofiltration in critically ill patients with a high risk of bleeding. Kidney Int 1999; 55:1991–7.

  • 6.

    Kutsogiannis DJ, Mayers I, Chin WD, Gibney RT. Regional citrate anticoagulation in continuous venous hemofiltration. Am J Kidney Dis 2000; 35:802–11.

  • 7.

    Mitchell A, Daul AE, Beiderlinden M, Schäfers RF, Heemann U, Kribben A, et al. A new system for regional citrate anticoagulation in continuous venous hemofiltration (CVVHD). Clin Nephrol 2003; 59:106–14.

  • 8.

    Dorval M, Madore F, Courteau S, Lablanc M. A novel citrate anticoagulation regimen for continuous venous hemofiltration. Intensive Care Med 2003; 29:1186–9.

  • 9.

    Mehta TL, McDonald BR, Ward DM. Regional citrate anticoagulation for continuous arteriovenous hemodialysis. An update after 12 months. Contrib Nephrol 1991; 93:210–4.

  • 10.

    Gabutti L, Marone C, Colucci G, Duchini F, Schönholzer C. Citrate anticoagulation in continuous venovenous hemofiltration: a metabolic challenge. Intensive Care Med 2002; 28:1419–25.

  • 11.

    Hofbauer R, Moser D, Frass M, Oberbauer R, Kaye AD, Wagner O, et al. Effect of anticoagulation on membrane interactions during hemodialysis. Kidney Int 1999; 56:1578–83.

  • 12.

    Pinnick RV, Wiegman TB, Diederich DA. Regional citrate anticoagulation for hemodialysis in the patient at high risk for bleeding. N Engl J Med 1983; 308:258–61.

  • 13.

    Kramer L, Bauer E, Joukhadar C, Strobl W, Gendo A, Madl C, et al. Citrate pharmacokinetics and metabolism in cirrhotic and noncirrhotic critically ill patients. Crit Care Med 2003; 31:2450–5.

  • 14.

    Meier-Krieske HU, Finkel KW, Gitomer JJ, DuBose TD. Unexpected severe hypocalcemia during continuous venovenous hemodialysis with regional citrate anticoagulation. Am J Kidney Dis 1999; 33:E8.

  • 15.

    Apsner R, Schwarzenhofer M, Derfler K, Zauner C, Ratheiser K, Kranz A. Impairment of citrate metabolism in acute hepatic failure. Wien Klin Wochenschr 1997; 109:123–7.

  • 16.

    Janssen M, Huijgens P, Bouman A, Oe P, Van der Meulen J. Citrate anticoagulation and divalent cations in hemodialysis. Blood Purif 1994; 12:308–16.

  • 17.

    Meier-Krieske HU, Gitomer J, Finkel K, DuBose T. Increased total to ionised calcium ratio during continuous venovenous hemodialysis with regional citrate anticoagulation. Crit Care Med 2001; 29:748–52.

  • 18.

    Slomp J, van der Voort PH, Gerritsen RT, Berk JA, Bakker AJ. Albumin-adjusted calcium is not suitable for the diagnosis of hyper- and hypocalcemia in the critically ill. Crit Care Med 2003; 31:1389–93.

  • 19.

    Möllering H, Gruber W. Determination of citrate with citrate lyase. Anal Biochem 1966; 17:369–76.

  • 20.

    McWhinney BC, Cowley DM, Chalmers AM. An automated method for measuring plasma citrate without protein precipitation. Clin Chem 1985; 31:1578–9.

  • 21.

    Borland WW, Ferguson JC, Dryburgh FJ. A fast automated method for measuring serum and urine citrate. Ann Clin Biochem 1989; 26:286–8.

  • 22.

    Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 1982; 143:29–36.

  • 23.

    Hanley JA, McNeil BJ. A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology 1983; 148:839–43.

  • 24.

    Diaz J, Acosta F, Parrilla P, Sansano T, Bento M, Cura S, et al. Citrate intoxication and blood concentration of ionised calcium in liver transplantation. Transplant Proc 1994; 26:3669–70.

  • 25.

    Diaz J, Acosta F, Parrilla P, Sansano T, Contreras RF, Bueno FS, et al. Correlation among ionised calcium, citrate, and total calcium levels during hepatic transplantation. Clin Biochem 1995; 28:315–7.

  • 26.

    Mehta RL, McDonald BR, Aguilar MM, Ward DM. Regional citrate anticoagulation for continuos arteriovenous hemodialysis in critically ill patients. Kidney Int 1990; 38:976–81.

  • 27.

    Tolwani AJ, Campbell RC, Schenk MB, Allon M, Warnock DG. Simplified citrate anticoagulation for continuous renal replacement therapy. Kidney Int 2001; 60:370–4.

Purchase article
Get instant unlimited access to the article.
$42.00
Log in
Already have access? Please log in.


or
Log in with your institution

Journal + Issues

Clinical Chemistry and Laboratory Medicine ( CCLM) publishes articles on novel teaching and training methods applicable to laboratory medicine. CCLM welcomes contributions on the progress in fundamental and applied research and cutting-edge clinical laboratory medicine. It is one of the leading journals in the field, with an impact factor of over three. CCLM is the official journal of nine national clinical societies and associated with EFLM.

Search